ClinicalTrials.gg
Active, not recruitingNCT07128121Updated Nov 18, 2026

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

A Phase 2 interventional study of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) and Placebo in Respiratory Syncytial Virus (RSV) Infection, sponsored by Shenzhen Shenxin Biotechnology Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shenzhen Shenxin Biotechnology Co., Ltd · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV) Infection

Keywords

  • mRNA Vaccine
  • IN006
  • Respiratory syncytial virus
  • RSV
  • Viral Diseases
  • Messenger RNA
  • Innorna
  • Shenxin
  • Vaccines
  • Respiratory tract infections
  • Safety
  • Reactogenicity
  • Immunogenicity
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's planned enrollment of 500 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Shenzhen Shenxin Biotechnology Co., Ltd is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy participants aged ≥60 years, male or female.
  2. The participants signed the form, and were able to provide valid identification documents. They also understood and complied with the requirements of the trial protocol.
  3. Female participants must be non-. If male participants have female partners of childbearing potential, they must agree to use effective from the signing of informed consent until 6 months after each vaccination.
  4. Participants must be capable of performing self-care and routine activities of daily living.

Exclusion criteria

Exclusion Criteria:

  1. (BMI) \<18 kg/m\^2 or ≥30 kg/m\^2.
  2. During the screening period, laboratory test results were abnormal and had clinical significance, or the severity reached or exceeded the Grade 2 criteria; or 12-lead results were abnormal and had clinical significance (except for heart rate, for which the criterion relevant to pulse rate in exclusion criterion #3 should be applied). (For laboratory tests, a retest can be conducted at the discretion of investigators to determine the eligibility of the participants).
  3. Vital signs meeting any of the following:

    • Systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg;
    • Poorly controlled hypertension: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
    • Pulse rate >100 beats per minute or \<50 beats per minute;
    • Axillary temperature >37.0°C.
  4. Tattoos, scars, bruises, or other conditions at the injection site that may interfere with local reaction assessment.
  5. Known allergy to the vaccine or its , or history of severe allergic reactions to other vaccines, foods, or medications.
  6. Previously received any investigational or licensed Respiratory Syncytial Virus (RSV) vaccine, or administration of investigational/licensed RSV prophylactic monoclonal antibodies within the last 6 months.
  7. Received inactivated, subunit, or recombinant influenza vaccine within 14 days prior to randomization, or any other vaccine within 28 days prior to randomization; Or plan to receive any vaccines within 28 days after the investigational vaccine.
  8. Use of antipyretics, analgesics, or anti-allergic drugs within 3 days prior to randomization.
  9. Have received blood or blood-related products (including immunoglobulins) within 3 months prior to randomization, or had planned to use during the trial.
  10. Participants with the following diseases (based on inquiry and/or relevant diagnosis):

    • A history of acute respiratory infection within 2 weeks of randomization; Or a history of confirmed RSV-associated respiratory infection within 3 months prior to vaccination; Or during the screening, RSV IgM is positive;
    • Any acute illness or acute exacerbation of a chronic illness within 3 days prior to randomization;
    • History of congenital or acquired immune deficiency or diseases, or long-term use (continuous use > 14 days) of (dose ≥ 20mg/day prednisone or equivalent dose) or other within the past 6 months;
    • Participants who have been diagnosed with or currently have an infectious disease (including , , and acquired immune deficiency syndrome), those who currently have active tuberculosis, or those whose tests for hepatitis B surface antigen, hepatitis C antibody, or antibody are positive;
    • Previous or current neurological disorders (excluding seizures other than febrile seizures in children, and other types of epilepsy); History or family history of mental illness;
    • Asplenia, or functional asplenia;
    • Have a history of myocarditis, pericarditis or idiopathic cardiomyopathy, or have any disease that increases the risk of myocarditis or pericarditis;
    • Has a history of inflammatory demyelinating neurological disorders such as Guillain-Barré syndrome;
    • Has severe or unstable cardiovascular diseases, diabetes, diseases of the blood and lymphatic systems, immune system diseases, liver and kidney diseases, respiratory diseases, metabolic and skeletal diseases, or malignant tumors;
    • Has for intramuscular injections and blood drawing;
  11. Have a history of major surgery within 3 months prior to randomization or planned surgery during the trial.
  12. Drug/alcohol abuse within 1 year prior to randomization, deemed by investigators to impact safety assessment or compliance.
  13. Have received lipid nanoparticle (LNP)-based vaccines/medications within 1 year prior to randomization; current participation in other RSV-related trials; OR planned to participate in other clinical trials during this study.
  14. The investigators evaluated that any disease or condition of the participants might place them at an unacceptable risk; The participants failed to meet the requirements of the protocol; circumstances that interfered with the assessment of the vaccine response.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    IN006 Dose A (Arm 1)

    One injection of Dose A of IN006 on Day 0. Participants will be further randomized to receive a second injection of either IN006 at Dose A or matching-placebo approximately 12 months later. Participants receive a second injection of placebo will be further randomized to receive a third injection of either IN006 at Dose A or matching-placebo approximately 24 months later.

    Biological: Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)

  • Experimental
    IN006 Dose B (Arm 2)

    One injection of Dose B of IN006 on Day 0. Participants will be further randomized to receive a second injection of either IN006 at Dose B or matching-placebo approximately 12 months later. Participants receive a second injection of placebo will be further randomized to receive a third injection of either IN006 at Dose B or matching-placebo approximately 24 months later.

    Biological: Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)

  • Placebo comparator
    Placebo (Arm 3)

    Placebo On injection of placebo on Day 0.

    Biological: Placebo

Interventions

  • BiologicalRespiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)

    Formulation for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Local and Systemic Adverse Reactions Through 14 Days After Initial Vaccination

    Time frame: From initial vaccination up to14 days post initial vaccination

  2. Percentage of Participants With Unsolicited Adverse Events (AEs) Through 28 Days After Initial Vaccination

    Time frame: From initial vaccination up to 28 days post initial vaccination

  3. Percentage of Participants With Unsolicited AEs Through 30 Minutes After Initial Vaccination

    Time frame: From initial vaccination up to 30 minutes post initial vaccination

  4. Percentage of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) During Study

    Time frame: Through study completion, about 3 years at most

  5. Percentage of Abnormal Results of Hematology On Day 3 After Initial Vaccination Compared with Baseline

    Time frame: From initial vaccination up to 3 days post initial vaccination

  6. Percentage of Abnormal Results of Clinical Chemistry On Day 3 After Initial Vaccination Compared with Baseline

    Time frame: From initial vaccination up to 3 days post initial vaccination

  7. Percentage of Abnormal Results of Coagulation On Day 3 After Initial Vaccination Compared with Baseline

    Time frame: From initial vaccination up to 3 days post initial vaccination

  8. Percentage of Participants With Any AEs Leading to Discontinuation of Vaccination or Withdrawal From The Study

    Time frame: Through study completion, about 3 years at most

  9. Geometric mean concentration (GMC) for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: 1 month post-initial vaccination

  10. Geometric Mean Fold Rise (GMFR) for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: 1 month post-initial vaccination

  11. Seroconversion Rate (SCR) for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: 1 month post-initial vaccination

  12. Geometric mean titer (GMT) for Neutralizing Antibody Against RSV A and RSV B

    Time frame: 1 month post-initial vaccination

  13. GMFR for Neutralizing Antibody Against RSV A and RSV B

    Time frame: 1 month post-initial vaccination

  14. SCR for Neutralizing Antibody Against RSV A and RSV B

    Time frame: 1 month post-initial vaccination

Secondary outcomes

  1. GMC for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: 3, 6 and 12 months post-initial vaccination

  2. GMFR for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: 3, 6 and 12 months post-initial vaccination

  3. SCR for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: 3, 6 and 12 months post-initial vaccination

  4. GMT for Neutralizing Antibody Against RSV A and RSV B

    Time frame: 3, 6 and 12 months post-initial vaccination

  5. GMFR for Neutralizing Antibody Against RSV A and RSV B

    Time frame: 3, 6 and 12 months post-initial vaccination

  6. SCR for Neutralizing Antibody Against RSV A and RSV B

    Time frame: 3, 6 and 12 months post-initial vaccination

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2029, 50 months after the start.

Of 42 industry-sponsored phase 2 interventional studies under Infections, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 19. This study's planned 50 months is above that.

Counting every sponsor, half of 77 studies reached it within 16 months; a quarter within 10 and three quarters within 47.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 17, 2025
StartActual
Aug 13, 2025
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07128121
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Aug 13, 2025
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion